Literature DB >> 27091970

Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.

Katrin H Preller1, Thomas Pokorny2, Andreas Hock3, Rainer Kraehenmann2, Philipp Stämpfli4, Erich Seifritz5, Milan Scheidegger2, Franz X Vollenweider2.   

Abstract

Social ties are crucial for physical and mental health. However, psychiatric patients frequently encounter social rejection. Moreover, an increased reactivity to social exclusion influences the development, progression, and treatment of various psychiatric disorders. Nevertheless, the neuromodulatory substrates of rejection experiences are largely unknown. The preferential serotonin (5-HT) 2A/1A receptor agonist, psilocybin (Psi), reduces the processing of negative stimuli, but whether 5-HT2A/1A receptor stimulation modulates the processing of negative social interactions remains unclear. Therefore, this double-blind, randomized, counterbalanced, cross-over study assessed the neural response to social exclusion after the acute administration of Psi (0.215 mg/kg) or placebo (Pla) in 21 healthy volunteers by using functional magnetic resonance imaging (fMRI) and resting-state magnetic resonance spectroscopy (MRS). Participants reported a reduced feeling of social exclusion after Psi vs. Pla administration, and the neural response to social exclusion was decreased in the dorsal anterior cingulate cortex (dACC) and the middle frontal gyrus, key regions for social pain processing. The reduced neural response in the dACC was significantly correlated with Psi-induced changes in self-processing and decreased aspartate (Asp) content. In conclusion, 5-HT2A/1A receptor stimulation with psilocybin seems to reduce social pain processing in association with changes in self-experience. These findings may be relevant to the normalization of negative social interaction processing in psychiatric disorders characterized by increased rejection sensitivity. The current results also emphasize the importance of 5-HT2A/1A receptor subtypes and the Asp system in the control of social functioning, and as prospective targets in the treatment of sociocognitive impairments in psychiatric illnesses.

Entities:  

Keywords:  functional magnetic resonance imaging; magnetic resonance spectroscopy; psilocybin; serotonin; social cognition

Mesh:

Substances:

Year:  2016        PMID: 27091970      PMCID: PMC4983864          DOI: 10.1073/pnas.1524187113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  71 in total

Review 1.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.

Authors:  Franz X Vollenweider; Michael Kometer
Journal:  Nat Rev Neurosci       Date:  2010-08-18       Impact factor: 34.870

2.  The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs.

Authors:  Maurizio S Riga; Guadalupe Soria; Raúl Tudela; Francesc Artigas; Pau Celada
Journal:  Int J Neuropsychopharmacol       Date:  2014-03-20       Impact factor: 5.176

3.  Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors.

Authors:  M Victoria Puig; Akiya Watakabe; Mika Ushimaru; Tetsuo Yamamori; Yasuo Kawaguchi
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

4.  Cyberostracism: effects of being ignored over the Internet.

Authors:  K D Williams; C K Cheung; W Choi
Journal:  J Pers Soc Psychol       Date:  2000-11

5.  Association of different adverse life events with distinct patterns of depressive symptoms.

Authors:  Matthew C Keller; Michael C Neale; Kenneth S Kendler
Journal:  Am J Psychiatry       Date:  2007-10       Impact factor: 18.112

6.  The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions.

Authors:  André Schmidt; Michael Kometer; Rosilla Bachmann; Erich Seifritz; Franz Vollenweider
Journal:  Psychopharmacology (Berl)       Date:  2012-07-27       Impact factor: 4.530

7.  Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.

Authors:  Robin L Carhart-Harris; David Erritzoe; Tim Williams; James M Stone; Laurence J Reed; Alessandro Colasanti; Robin J Tyacke; Robert Leech; Andrea L Malizia; Kevin Murphy; Peter Hobden; John Evans; Amanda Feilding; Richard G Wise; David J Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 8.  A quantitative meta-analysis of functional imaging studies of social rejection.

Authors:  Stephanie Cacioppo; Chris Frum; Erik Asp; Robin M Weiss; James W Lewis; John T Cacioppo
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

9.  Connectivity, pharmacology, and computation: toward a mechanistic understanding of neural system dysfunction in schizophrenia.

Authors:  Alan Anticevic; Michael W Cole; Grega Repovs; Aleksandar Savic; Naomi R Driesen; Genevieve Yang; Youngsun T Cho; John D Murray; David C Glahn; Xiao-Jing Wang; John H Krystal
Journal:  Front Psychiatry       Date:  2013-12-24       Impact factor: 4.157

10.  Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study.

Authors:  Cédric M Hysek; Linda D Simmler; Valentina G Nicola; Nerina Vischer; Massimiliano Donzelli; Stephan Krähenbühl; Eric Grouzmann; Jörg Huwyler; Marius C Hoener; Matthias E Liechti
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

View more
  41 in total

Review 1.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Neural correlates of social exclusion across ages: A coordinate-based meta-analysis of functional MRI studies.

Authors:  Nandita Vijayakumar; Theresa W Cheng; Jennifer H Pfeifer
Journal:  Neuroimage       Date:  2017-02-21       Impact factor: 6.556

3.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

4.  Social exclusion reliably engages the default network: A meta-analysis of Cyberball.

Authors:  Laetitia Mwilambwe-Tshilobo; R Nathan Spreng
Journal:  Neuroimage       Date:  2020-12-29       Impact factor: 6.556

5.  Perceived burdensomeness and neural responses to ostracism in the Cyberball task.

Authors:  Thang M Le; Simon Zhornitsky; Wuyi Wang; Chiang-Shan R Li
Journal:  J Psychiatr Res       Date:  2020-07-28       Impact factor: 4.791

6.  Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings.

Authors:  Matthias Forstmann; Daniel A Yudkin; Annayah M B Prosser; S Megan Heller; Molly J Crockett
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-21       Impact factor: 11.205

Review 7.  Empathy as a Concept from Bench to Bedside: A Translational Challenge.

Authors:  Nazan Uysal; Ulaş M Çamsari; Mehmet ATEş; Sevim Kandİş; Aslı Karakiliç; Gamze B Çamsari
Journal:  Noro Psikiyatr Ars       Date:  2019-11-28       Impact factor: 1.339

8.  Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.

Authors:  Anya K Bershad; Scott T Schepers; Michael P Bremmer; Royce Lee; Harriet de Wit
Journal:  Biol Psychiatry       Date:  2019-06-03       Impact factor: 13.382

9.  Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study.

Authors:  Katrin H Preller; Leonhard Schilbach; Thomas Pokorny; Jan Flemming; Erich Seifritz; Franz X Vollenweider
Journal:  J Neurosci       Date:  2018-03-19       Impact factor: 6.167

Review 10.  Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways.

Authors:  Juan F López-Giménez; Javier González-Maeso
Journal:  Curr Top Behav Neurosci       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.